Charles River holder plans sale of 573 shares

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

Rhea-AI Filing Summary

CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) is the issuer for which a holder, Nancy C. Andrews, has filed a notice of proposed sale under Rule 144. The notice covers the potential sale of 573 shares of common stock, with an aggregate market value of 163,305, out of 48,167,730 shares outstanding, through UBS Financial Services Inc., with an approximate sale date of 08/18/2026 following a stock option exercise.

Key Figures

Shares to be sold: 573 shares Aggregate market value: 163,305 Shares outstanding: 48,167,730 shares +2 more

5 metrics

Shares to be sold 573 shares Number of CRL common shares covered by the Rule 144 notice

Aggregate market value 163,305 Aggregate market value of the 573 CRL shares to be sold

Shares outstanding 48,167,730 shares CRL common shares outstanding referenced in the Rule 144 notice

Approximate sale date 08/18/2026 Approximate date of proposed sale of the 573 CRL shares

Acquisition date 08/18/2026 Date of stock option exercise through which the 573 shares were acquired

Key Terms

Rule 144, stock option exercise, attorney-in-fact

3 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

stock option exercise financial

"Common Stock | 08/18/2026 | Stock Option Exercise | Charles River Laboratories"

A stock option exercise is the act of using a previously granted right to buy shares of a company's stock at a specific, predetermined price by paying that price and receiving the shares. It matters to investors because exercising changes who owns the shares (which can dilute existing ownership), can trigger taxable events and shift potential gains or losses, and affects voting power and the company’s outstanding share count—like turning a voucher into an actual product that becomes part of circulating supply.

attorney-in-fact regulatory

"for UBS Financial Services Inc, as attorney-in-fact for Nancy C Andrews"

An attorney-in-fact is the person or entity given legal authority through a power of attorney to act on behalf of another for specific tasks, such as signing documents, voting shares, or handling transactions. For investors, this matters because it lets a trusted representative make timely decisions or complete paperwork when the owner cannot, much like handing keys to someone to run errands on your behalf—so checks on scope and limits of that authority are important.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 144 filing for CRL disclose about planned share sales?

The filing discloses a planned sale of 573 CRL common shares under Rule 144. These shares are held for the account of Nancy C. Andrews and are expected to be sold through UBS Financial Services Inc. around 08/18/2026.

How many Charles River Laboratories (CRL) shares are covered by this Form 144?

The notice covers 573 shares of Charles River Laboratories common stock. This amount is small compared with the reported 48,167,730 shares outstanding, indicating a limited relative size for this proposed sale.

What is the aggregate market value of the CRL shares in this Form 144?

The aggregate market value of the 573 CRL shares covered is listed as 163,305. This figure reflects the total market value of the shares proposed to be sold under Rule 144 at the time of the notice.

When are the CRL shares in this Form 144 expected to be sold?

The approximate sale date indicated is 08/18/2026. This date applies to the proposed Rule 144 sale of the 573 CRL common shares, which are associated with a stock option exercise paid for in cash.

How were the CRL shares in this Form 144 acquired?

The 573 CRL shares were acquired via a stock option exercise on 08/18/2026, with the consideration paid in cash. After exercise, a notice was filed to permit their potential resale under Rule 144.

Who is executing the planned Rule 144 sale of CRL shares?

The proposed sale is to be executed through UBS Financial Services Inc.. UBS is listed as the broker for the Rule 144 transaction involving 573 Charles River Laboratories common shares held for Nancy C. Andrews’ account.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/18/2026 - 11:06 AM EDT Accepted by SEC EDGAR 08/18/2026 - 11:06 AM EDT Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001804999
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Charles River Laboratories International
SEC File Number	001-15943
Address of Issuer	251 Ballardvale Street Wilmington MASSACHUSETTS 01887
Phone	4242153534
Name of Person for Whose Account the Securities are To Be Sold	Nancy C Andrews
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Director

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	UBS Financial Services Inc 1000 Harbor Blvd 3rd Floor Weehawken NJ 07086	573	163305	48167730	08/18/2026	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	08/18/2026	Stock Option Exercise	Charles River Laboratories International, Inc.			573	08/18/2026	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks
Date of Notice	08/18/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/Mijo Suric, for UBS Financial Services Inc, as attorney-in-fact for Nancy C Andrews
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)